Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02287467
Other study ID # INSIGHT 006: FLU-IVIG
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date January 2015
Est. completion date June 7, 2018

Study information

Verified date November 2019
Source National Institute of Allergy and Infectious Diseases (NIAID)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Influenza (the flu) is a common illness that usually occurs in autumn and winter. The flu is usually mild, but can cause serious illness or death. The purpose of this study is to test the safety and effectiveness of an antibody against the flu (called intravenous hyperimmune immunoglobulin or IVIG) in people who are hospitalized for severe flu.


Description:

Influenza is responsible for thousands of hospitalizations and deaths each year in the United States and worldwide. One possible new treatment for the flu involves the use of IVIG, a blood product containing antibodies from people who have recovered from the flu or who have had a flu shot. The purpose of this study is to evaluate whether IVIG can reduce the severity and duration of flu in people who are hospitalized with the flu.

The study will enroll participants 18 years and older who are hospitalized with the flu. The study will enroll participants over one or more flu seasons. Regardless of the date of enrollment, each participant will be in the study for about 28 days.

At study entry (Day 0), participants will be randomly assigned to one of two groups (Arms A and B). Participants in both groups will receive standard of care (SOC) treatment for the flu, but those in Arm A will also receive one dose of IVIG and those in Arm B will receive a placebo for IVIG. Both IVIG and placebo will be given intravenously over at least 2 hours.

On Day 0, before receiving IVIG or placebo, participants will undergo a symptoms assessment, blood collection, and a nasopharyngeal (NP) swab to collect a sample of secretions from the nose and throat.

Additional study visits will occur on Days 1, 2, 3, 7, 14, and 28. Depending on the visit, participants may take part in the same study procedures that took place on Day 0. On Days 2, 14, and 28, visits for participants who are no longer hospitalized may be conducted over the phone.


Recruitment information / eligibility

Status Completed
Enrollment 329
Est. completion date June 7, 2018
Est. primary completion date June 7, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Signed informed consent

- Locally determined positive influenza test (by polymerase chain reaction [PCR] or other nucleic acid test, or by rapid antigen [Ag]) from a specimen obtained within 2 days prior to randomization

- Onset of illness no more than 7 days before randomization, defined as when the participant first experienced at least one respiratory symptom or fever

- Hospitalized (or in observation unit) for influenza, with anticipated hospitalization for more than 24 hours. Criteria for hospitalization will be up to the individual treating clinician.

- For women of child-bearing potential: willingness to abstain from sexual intercourse or use at least one form of hormonal or barrier contraception through Day 28 of the study

- Willingness to have blood and respiratory samples obtained and stored

- NEW score greater than or equal to 2 at screening (see the protocol for more information on this criterion)

Exclusion Criteria:

- Women who are pregnant or breast-feeding

- Strong clinical evidence (in the judgment of the site investigator) that the etiology of illness is primarily bacterial in origin

- Prior treatment with any investigational drug therapy within 30 days prior to screening

- History of allergic reaction to blood or plasma products (as judged by the site investigator)

- Known immunoglobulin A (IgA) deficiency

- A pre-existing condition or use of a medication that, in the opinion of the site investigator, may place the participant at a substantially increased risk of thrombosis (e.g., cryoglobulinemia, severe refractory hypertriglyceridemia, or clinically significant monoclonal gammopathy)

- Presence of any pre-existing illness that, in the opinion of the site investigator, would place the participant at an unreasonably increased risk through participation in this study

- Participants who, in the judgment of the site investigator, will be unlikely to comply with the requirements of this protocol

- Medical conditions for which receipt of a 500 mL volume of intravenous fluid may be dangerous to the participant (e.g., decompensated congestive heart failure)

- Receiving extracorporeal membrane oxygenation (ECMO)

- Suspicion that infection is due to an influenza strain or subtype other than A(H1N1)pdm09, H3N2, or influenza B (e.g., H5N1, H7N9)

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Intravenous hyperimmune immunoglobulin (IVIG)
Administered intravenously (IV) at a dose of 0.25 g/kg (up to a maximum of 24.75 g, corresponding to approximately 100 kg actual body weight)
Placebo for IVIG
Administered IV as 500 mL of normal saline

Locations

Country Name City State
Australia Westmead Hospital Sydney
Denmark Odense University Hospital Odense
United Kingdom St James's University Hospital Leeds
United Kingdom Churchill Hospital Oxford
United States National Institutes of Health Clinical Center Bethesda Maryland
United States Montefiore Medical Center Bronx New York
United States Cooper University Hospital Camden New Jersey
United States University of Illinois Chicago Illinois
United States Case Western Reserve University Cleveland Ohio
United States OHIO State University (OSU) Wexner Medical Center Columbus Ohio
United States UT Southwestern Medical Center Dallas Texas
United States Miami Valley Hospital Dayton Ohio
United States Denver Public Health Denver Colorado
United States Henry Ford Hospital Detroit Michigan
United States Duke University Durham North Carolina
United States Minneapolis VA Medical Center Minneapolis Minnesota
United States West Virginia University Morgantown West Virginia
United States Cornell CRS New York New York
United States University of Pittsburgh Pittsburgh Pennsylvania
United States Mayo Clinic Rochester Minnesota
United States UCSD Antiviral Research Center (A VRC) San Diego California

Sponsors (3)

Lead Sponsor Collaborator
National Institute of Allergy and Infectious Diseases (NIAID) International Network for Strategic Initiatives in Global HIV Trials (INSIGHT), University of Minnesota

Countries where clinical trial is conducted

United States,  Australia,  Denmark,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Patients in Each of 6 Clinical Status Categories on Day 7 This is the primary outcome, a 6-category ordinal outcome ranging from death (worst) to discharged from hospital with resumption of normal activities (best). Assessed on Day 7
Secondary Number of Patients in Each of 5 Clinical Status Categories on Day 3 5-category ordinal outcome assessed on day 3; clinical status ranges from death (worst) to discharged from the hospital (best). Assessed on Day 3
Secondary Number of Patients in Each of 6 Clinical Status Categories on Day 3 6-category ordinal outcome evaluated on Day 3; clinical status ranges from death (worst) to discharged from hospital with resumption of normal activities (best). Measured on Day 3
Secondary Number of Patients With a Favorable Outcome on Day 7 Sliding dichotomy defined as non-ICU hospitalization or discharge if enrolled from ICU, and discharge if enrolled from the general ward. Assessed on Day 7
Secondary Hospital Discharge Number of participants alive and discharged from the hospital Measured through Day 7
Secondary Mortality Number of participants dying through day 28. Measured through day 28
Secondary Number of Patients Alive and Out of Hospital Number and percent alive and out of hospital on day 28 Measured through Day 28
Secondary Change in Viral Load Change in nasopharyngeal viral load from baseline to day 3 Day 3
Secondary Death or Re-hospitalization Number and percent of participants who died or were re-hospitalized after initial discharge Day 28
Secondary Percent of Participants Developing Complications Number and percent of participants developing respiratory distress syndrome, acute renal failure, sepsis, pneumonia, enteritis, or bronchitis Measured through Day 28
Secondary Number of Patients in Each of 6 Clinical Status Categories on Day 14 6-category ordinal outcome measured on day 14 Measured on day 14
Secondary Number of Patients Alive and Out of Hospital on Day 14 Number and percentage of participants alive and out of the hospital on Day 14 day 14
Secondary Resumption of Normal Activities by Day 14 Participants reporting resumption of normal daily activities by Day 14 day 14
Secondary Number of Patients in Each of 6 Clinical Status Categories on Day 28 6-category ordinal outcome corresponding to clinical status on day 28 day 28
Secondary Number of Influenza A-Infected Patients in Each of 6 Clinical Status Categories on Day 7 Primary 6-category ordinal outcome for participants infected with Influenza A Day 7
Secondary Number of Influenza B-Infected Patients in Each of 6 Clinical Status Categories on Day 7 Primary 6-category ordinal outcome for subgroup of participants infected with influenza B Day 7
Secondary pH1N1 Titers at Day 7 pH1N1 hemagglutination inhibition assay (HAI) titers among participants infected with pH1N1 using A/Cal/2009 as reference virus Day 7
Secondary H3N2 Titers at Day 7 H3N2 HAI titers among participants infected with H3N2 using A/HongKong/2014 as reference virus Day 7
Secondary Influenza B Titers at Day 7 Flu B HAI titers among participants infected with influenza B using B/Phuket/2013 as reference virus Day 7
See also
  Status Clinical Trial Phase
Completed NCT03999554 - Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines Phase 1
Completed NCT06385821 - A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus Phase 3
Completed NCT02487173 - Validation of the Respirio Flu Test for the Rapid Identification of Influenza A/B N/A
Completed NCT01701752 - Influenza A Vaccine (FP-01.1) Formulated With and Without Adjuvant, in the Presence or Absence of a Single Administration of a Trivalent Inactivated Influenza Virus Vaccine in Older Adults Phase 1
Enrolling by invitation NCT03207152 - Biomarkers Predicting Infectivity in an Experimental Human Influenza Model Phase 1
Terminated NCT05567783 - A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A Phase 2
Not yet recruiting NCT00987012 - The Influence of Fortified Pomegranate Juice (Punica Granatum) on Seasonal Influenza and Swine Flu Patients N/A
Not yet recruiting NCT05928507 - FINDER® Instrument and FINDER® FLU A/B, RSV, SARS-CoV-2 Test Clinical Evaluation Protocol
Completed NCT03651544 - The Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac Phase 1
Completed NCT02623322 - A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy Adults Phase 2
Completed NCT03196661 - Preliminary Study on Safety and Immunogenicity of Influenza A (H7N9) Vaccine in the Population Phase 1
Recruiting NCT06160531 - Influenza Viral Challenge Study of CC-42344 in Healthy Participants Phase 2
Recruiting NCT06191393 - SARS-CoV-2 and Influenza A/B in Point-of-Care and Non-Laboratory Settings N/A
Completed NCT06127108 - Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Panel N/A
Completed NCT05163730 - Clinical Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel N/A
Not yet recruiting NCT06392451 - LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in Symptomatic Patients in Australia N/A
Recruiting NCT04896853 - Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans® Phase 1
Not yet recruiting NCT05787444 - Clinical Validation of the LumiraDx SARS-CoV-2 & Flu A/B Test in Detecting and Differentiating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Influenza A (Flu A), and/or Influenza B (Flu B)
Completed NCT05354115 - Sample Collection for Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel. N/A
Completed NCT02014870 - Safety and Reactogenicity of a H1N1 Influenza Challenge Virus in Healthy Volunteers Phase 1